Skip to content
Kurome Therapeutics
  • Science
  • Team
  • Partnering
  • Contact
  • News
Menu
  • Science
  • Team
  • Partnering
  • Contact
  • News

aisoftware

Kurome Therapeutics

Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)

Research Papers / aisoftware

Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) Read More »

Kurome Therapeutics

Double trouble: IRAK1/4 inhibitors in AML/MDS

Research Papers / aisoftware

Double trouble: IRAK1/4 inhibitors in AML/MDS Read More »

Kurome Therapeutics

KUROME THERAPEUTICS TARGETS DYSREGULATED IMMUNE SIGNALING IN BLOOD CANCER PATIENTS

Press Release / aisoftware

KUROME THERAPEUTICS TARGETS DYSREGULATED IMMUNE SIGNALING IN BLOOD CANCER PATIENTS Read More »

Recent Posts

  • Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)
  • Double trouble: IRAK1/4 inhibitors in AML/MDS
  • KUROME THERAPEUTICS TARGETS DYSREGULATED IMMUNE SIGNALING IN BLOOD CANCER PATIENTS
  • Paralog-Specific Signaling By IRAK1/4 Maintains MyD88-Independent Functions In MDS/AML
  • Activation Of Targetable Inflammatory Immune Signaling Is Seen In Myelodysplastic Syndromes With SF3B1 Mutations

Recent Comments

No comments to show.

Archives

  • February 2024
  • September 2023
  • May 2023
  • August 2022
  • July 2022
  • February 2022
  • January 2022
  • October 2021
  • February 2021
  • January 2021
  • April 2020
  • September 2019
  • August 2019
  • October 2018
  • December 2015
  • October 2014
  • April 2014
  • July 2013

Categories

  • News Articles
  • Presentations
  • Press Release
  • Research Papers
Kurome Therapeutics
  • Science
  • Team
  • Partnering
  • News
  • Contact Us
  • Science
  • Team
  • Partnering
  • News
  • Contact Us

Accessibility | Privacy | Terms

© 2023 Kurome® Therapeutics. All rights reserved.
Kurome is a registered trademark of Kurome Therapeutics. All rights reserved.